Cargando…
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer
The BRAF V600E mutation causes impaired expression of sodium iodide symporter (NIS) and radioiodine refractoriness of thyroid cancer, but the underlying mechanism remains undefined. In this study, we hypothesized that histone deacetylation at the NIS (SLC5A5) promoter was the mechanism. Using the ch...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920838/ https://www.ncbi.nlm.nih.gov/pubmed/24243688 http://dx.doi.org/10.1530/ERC-13-0399 |
_version_ | 1782303235097231360 |
---|---|
author | Zhang, Zongjing Liu, Dingxie Murugan, Avaniyapuram Kannan Liu, Zhimin Xing, Mingzhao |
author_facet | Zhang, Zongjing Liu, Dingxie Murugan, Avaniyapuram Kannan Liu, Zhimin Xing, Mingzhao |
author_sort | Zhang, Zongjing |
collection | PubMed |
description | The BRAF V600E mutation causes impaired expression of sodium iodide symporter (NIS) and radioiodine refractoriness of thyroid cancer, but the underlying mechanism remains undefined. In this study, we hypothesized that histone deacetylation at the NIS (SLC5A5) promoter was the mechanism. Using the chromatin immunoprecipitation approach, we examined histone acetylation status on the lysine residues H3K9/14, H3K18, total H4, and H4K16 at the NIS promoter under the influence of BRAF V600E. We found that expression of stably or transiently transfected BRAF V600E inhibited NIS expression while the deacetylase inhibitor SAHA stimulated NIS expression in PCCL3 rat thyroid cells. Although BRAF V600E enhanced global histone acetylation, it caused histone deacetylation at the NIS promoter while SAHA caused acetylation in the cells. In human thyroid cancer BCPAP cells harboring homozygous BRAF V600E mutation, BRAF V600E inhibitor, PLX4032, and MEK inhibitor, AZD6244, increased histone acetylation of the NIS promoter, suggesting that BRAF V600E normally maintained histone in a deacetylated state at the NIS promoter. The regions most commonly affected with deacetylation by BRAF V600E were the transcriptionally active areas upstream of the translation start that contained important transcription factor binding sites, including nucleotides −297/−107 in the rat NIS promoter and −692/−370 in the human NIS promoter. Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS silencing involving histone deacetylation at critical regulatory regions of the NIS promoter but also provide further support for our previously proposed combination therapy targeting major signaling pathways and histone deacetylase to restore thyroid gene expression for radioiodine treatment of thyroid cancer. |
format | Online Article Text |
id | pubmed-3920838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-39208382014-04-01 Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer Zhang, Zongjing Liu, Dingxie Murugan, Avaniyapuram Kannan Liu, Zhimin Xing, Mingzhao Endocr Relat Cancer Research The BRAF V600E mutation causes impaired expression of sodium iodide symporter (NIS) and radioiodine refractoriness of thyroid cancer, but the underlying mechanism remains undefined. In this study, we hypothesized that histone deacetylation at the NIS (SLC5A5) promoter was the mechanism. Using the chromatin immunoprecipitation approach, we examined histone acetylation status on the lysine residues H3K9/14, H3K18, total H4, and H4K16 at the NIS promoter under the influence of BRAF V600E. We found that expression of stably or transiently transfected BRAF V600E inhibited NIS expression while the deacetylase inhibitor SAHA stimulated NIS expression in PCCL3 rat thyroid cells. Although BRAF V600E enhanced global histone acetylation, it caused histone deacetylation at the NIS promoter while SAHA caused acetylation in the cells. In human thyroid cancer BCPAP cells harboring homozygous BRAF V600E mutation, BRAF V600E inhibitor, PLX4032, and MEK inhibitor, AZD6244, increased histone acetylation of the NIS promoter, suggesting that BRAF V600E normally maintained histone in a deacetylated state at the NIS promoter. The regions most commonly affected with deacetylation by BRAF V600E were the transcriptionally active areas upstream of the translation start that contained important transcription factor binding sites, including nucleotides −297/−107 in the rat NIS promoter and −692/−370 in the human NIS promoter. Our findings not only reveal an epigenetic mechanism for BRAF V600E-promoted NIS silencing involving histone deacetylation at critical regulatory regions of the NIS promoter but also provide further support for our previously proposed combination therapy targeting major signaling pathways and histone deacetylase to restore thyroid gene expression for radioiodine treatment of thyroid cancer. Bioscientifica Ltd 2014-04 /pmc/articles/PMC3920838/ /pubmed/24243688 http://dx.doi.org/10.1530/ERC-13-0399 Text en © 2014 The authors http://creativecommons.org/licenses/by/3.0/deed.en_GB This work is licensed under a Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/deed.en_GB) |
spellingShingle | Research Zhang, Zongjing Liu, Dingxie Murugan, Avaniyapuram Kannan Liu, Zhimin Xing, Mingzhao Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer |
title | Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer |
title_full | Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer |
title_fullStr | Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer |
title_full_unstemmed | Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer |
title_short | Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer |
title_sort | histone deacetylation of nis promoter underlies braf v600e-promoted nis silencing in thyroid cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920838/ https://www.ncbi.nlm.nih.gov/pubmed/24243688 http://dx.doi.org/10.1530/ERC-13-0399 |
work_keys_str_mv | AT zhangzongjing histonedeacetylationofnispromoterunderliesbrafv600epromotednissilencinginthyroidcancer AT liudingxie histonedeacetylationofnispromoterunderliesbrafv600epromotednissilencinginthyroidcancer AT muruganavaniyapuramkannan histonedeacetylationofnispromoterunderliesbrafv600epromotednissilencinginthyroidcancer AT liuzhimin histonedeacetylationofnispromoterunderliesbrafv600epromotednissilencinginthyroidcancer AT xingmingzhao histonedeacetylationofnispromoterunderliesbrafv600epromotednissilencinginthyroidcancer |